Among the most promising clinical trials, there is NCT05020678, a single-arm, open-label, multicenter, phase 1 study that is ongoing to evaluate the safety and tolerability of an experimental intravenous allogeneic CARNK cell targeting CD19 (NKX019) in adult patients (n = 60) with relapsed/refractory NHL, CLL or B-ALL. Here, CD19 is linked to non-Hodgkin lymphoma.